Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
BACKGROUND
The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS).


RESULTS
Among 559 lesions in 558 consecutive AMI from April 2003 to February 2006, the incidence of documented SAT after Cypher implantation (2/276 lesions, 0.72%) was almost the same as for BMS (2 cases, 0.71%). Aspirin (81-100 mg/day) plus ticlopidine (200 mg/day) were administered continuously after admission in all 4 cases.


CONCLUSIONS
Documented SAT did not increase after stenting with Cypher for AMI under aspirin plus ticlopidine.
Ishikawa
Tetsuya
T
Division of Cardiology, Saitama Prefecture Cardiovascular and Respiratory Center, Kohnan, Japan. ishikawa@jikei.ac.jp
Mutoh
Makoto
M
Fuda
Yuji
Y
Sakamoto
Hiroshi
H
Okada
Hisayuki
H
Higashitani
Michiaki
M
Nakano
Yousuke
Y
Yamaguchi
Junichi
J
Enta
Kenji
K
Satoh
Takahiro
T
Imai
Kamon
K
Horie
Toshinobu
T
Mochizuki
Seibu
S
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000150:complications; D003328:Coronary Thrombosis / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D018450:Disease Progression; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015994:Incidence; D008297:Male; D009203:Myocardial Infarction / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects*; D013988:Ticlopidine / Q000627:therapeutic use; D013997:Time Factors
D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin; D020123:Sirolimus